14789
-
Cancer Management and Research
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Review
(5479) Total Article Views
Authors: Verschraegen C
Published Date January 2012 Volume 2012:4 Pages 1 - 8
DOI: http://dx.doi.org/10.2147/CMAR.S15551
| Received: | 02 November 2011  |
|---|---|
| Accepted: | 05 December 2011 |
| Published: | 18 January 2012 |
Professor of Medicine, Division of Hematology Oncology, University of Vermont, Vermont Cancer Center, VT, USA
Background: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed against CTLA-4.
Objective: This review describes the basic mechanism of ipilimumab and discusses data available to date with regards to its safety and efficacy profile.
Methods: Data from clinical trials including abstracts was reviewed using the PubMed Database, as well as the American Society of Clinical Oncology Abstract Database.
Conclusion: CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and has efficacy as a therapeutic agent in a variety of cancers. The classical response interpretation has changed because of the delayed mechanism of action. The toxicities are autoimmune events and guidelines for treatment of these effects are discussed. Therapy with ipilimumab leads to durable responses. The first two Phase III randomized studies showed an improvement of survival at 1, 2, and 3 years. Other studies are currently underway to better understand the optimal treatment administration of ipilimumab in melanoma.
Keywords: melanoma, CTLA-4, ipilimumab, immune-related adverse events, melanoma, modified immune response criteria
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Cancer Management and Research
- The bradykinin B2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines
- Epigenomics in cancer management
- Serous endometrial intraepithelial carcinoma: a case series and literature review
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
